Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pitolisant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 17/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.97 |
| ▸ | HTR2C | P28335 | 1/20 | 0.97 |
| ▸ | HTR7 | P34969 | 1/20 | 0.97 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.97 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.97 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | RAD52 | P43351 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pitolisant SCHEMBL4591893 | 0.98 | HRH3 (1.00) | HRH3SLC6A2HRH1CHRM2ADRA2C | |
| Pitolisant SCHEMBL6570276 | 0.92 | HRH3 (0.85) | HRH3SLC6A2HRH1CHRM2ADRA2C | |
| Pitolisant SCHEMBL4592979 | 0.92 | HRH3 (0.85) | HRH3SLC6A2HRH1CHRM2ADRA2C | |
| SCHEMBL22561783 | 0.85 | HRH3 (0.74) | HRH3SLC6A2HRH1CHRM2ADRA2C | |
| SCHEMBL7982901 | 0.85 | HRH3 (0.73) | HRH3SLC6A2HRH1CHRM2ADRA2C | |
| SCHEMBL10054323 | 0.85 | HRH3 (0.74) | HRH3SLC6A2HRH1CHRM2ADRA2C | |
| SCHEMBL2451795 | 0.85 | HRH1 (0.74) | HRH3SLC6A2HRH1CHRM2ADRA2C | |
| SCHEMBL491655 | 0.84 | HRH3 (1.00) | HRH3SLC6A2HRH1CHRM2ADRA2C | |
| SCHEMBL491791 | 0.84 | HRH3 (0.72) | HRH3SLC6A2HRH1CHRM2ADRA2C | |
| SCHEMBL491979 | 0.83 | HRH3 (0.71) | HRH3SLC6A2HRH1CHRM2ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 678 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137689-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | ALTO NEUROSCIENCE INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260115178-A1 | STABLE PITOLISANT LIQUID FORMULATIONS AND METHOD OF ITS USE | PATEL SANDIPKUMAR ARVINDBHAI (US) | 2026-04-30 | — | — | US | claimed |
| WO-2026090627-A1 | STABLE PITOLISANT LIQUID FORMULATIONS AND METHOD OF ITS USE | PATEL SANDIPKUMAR (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4732903-A1 | CO-CRYSTALS OF PITOLISANT HYDROCHLORIDE | BIOPROJET Pharma (FR) | 2026-04-29 | — | — | EP | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20260034114-A1 | ENTERIC COATED PITOLISANT FORMULATIONS AND METHODS OF USE | BIOPROJET PHARMA (FR) | 2026-02-05 | — | — | US | claimed |
| EP-4681704-A1 | NEW FORMULATIONS OF PITOLISANT | BIOPROJET Pharma (FR) | 2026-01-21 | — | — | EP | claimed |
| EP-4673146-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | Biohaven Therapeutics Ltd. (VG) | 2026-01-07 | — | — | EP | claimed |
| US-20250367299-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ZEVRA THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | claimed |
| US-20250281475-A1 | A PHARMACEUTICAL COMPOSITION OF PITOLISANT HYDROCHLORIDE AND THEIR PROCESS FOR THE PREPARATION | MSN LABORATORIES PRIVATE LIMITED, R & D CENTER (IN) | 2025-09-11 | — | — | US | claimed |
| EP-1707204-A1 | Treatment of epilepsy with non-imidazole alkylamines histamine H3-receptor ligands | BIOPROJET (FR) | 2006-10-04 | — | — | EP | claimed |
| WO-2006084833-A1 | MONOHYDROCHLORIDE SALT OF 1- [3- [3- (4-CHLOROPHENYL) PROPOXY] PROPYL] -PIPERIDINE | BIOPROJET (FR) | 2006-08-17 | — | — | WO | claimed |
| EP-1690858-A1 | Monohydrochloride salt of 1-¬3-¬3-(4-chlorophenyl)propoxy|propyl|-piperidine | FERRER INTERNACIONAL, S.A. (ES) | 2006-08-16 | — | — | EP | claimed |
| EP-1428820-B1 | Non-imidazole alkylamines as histamine H-3-receptor ligands and their therapeutic applications | BIOPROJET SOC CIV (FR) | 2006-05-17 | — | — | EP | claimed |
| US-20040220225-A1 | central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants | SCHWARTZ JEAN-CHARLES (FR) | 2004-11-04 | — | — | US | claimed |
| EP-1100503-B1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ILE BIOPROJET SOC CIV (FR) | 2004-09-22 | — | — | EP | claimed |
| EP-1428820-A1 | Non-imidazole alkylamines as histamine H-3-receptor ligands and their therapeutic applications | BIOPROJET (FR) | 2004-06-16 | — | — | EP | claimed |
| EP-1100503-A2 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SOCIETE CIVILE BIOPROJET (FR) | 2001-05-23 | — | — | EP | claimed |
| EP-0982300-A2 | Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications | SOCIETE CIVILE BIOPROJET (FR) | 2000-03-01 | — | — | EP | claimed |
| WO-2000006254-A2 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SOCIETE CIVILE BIOPROJET (FR) | 2000-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115178-A1 | STABLE PITOLISANT LIQUID FORMULATIONS AND METHOD OF ITS USE | SLC6A6, SLC6A13, ABCG2 | HRH3 99/4885SLC6A2 26/4885HRH1 61/4885 |
| US-20260137689-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | CHRNA5, CHRNA2, CHRNA4 | HRH3 49/4885SLC6A2 75/4885HRH1 124/4885 |
| US-20260034114-A1 | ENTERIC COATED PITOLISANT FORMULATIONS AND METHODS OF USE | ATG13, WIZ, SI | HRH3 292/4885SLC6A2 142/4885HRH1 456/4885 |
| US-20250281475-A1 | A PHARMACEUTICAL COMPOSITION OF PITOLISANT HYDROCHLORIDE AND THEIR PROCESS FOR THE PREPARATION | GABARAPL1, ADCYAP1R1, VPS51 | HRH3 53/4885SLC6A2 270/4885HRH1 189/4885 |
| US-20040220225-A1 | central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants | HTR1A, HRH4, HTR1D | HRH3 6/4885SLC6A2 96/4885HRH1 7/4885 |
| US-20250367299-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | HSD17B10, HSD17B12, HSD17B14 | HRH3 2154/4885SLC6A2 962/4885HRH1 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.